FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Greetings and welcome to the X4 Pharmaceuticals fourth quarter and full year 2024 financial and operating results conference call. (Operator Instructions) and it is now my pleasure to turn to your ...

WASHINGTON, DC – The U.S. Department of Justice has charged Indian chemical manufacturer Vasudha Pharma Chem Limited (VPC) ...

Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.

As Robert F. Kennedy Jr. settles into his role as President Donald Trump’s health secretary, one major promise he’s made is ...

MM+M Agency 100 issue is nominated for Best Single Issue of a Tabloid/Newspaper/Magazine for a brand with revenue between $3 ...

The PMCPA has dug into the industry’s LinkedIn activities once again. | The PMCPA has dug into the industry’s LinkedIn ...